.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,875,704

« Back to Dashboard

Claims for Patent: 8,875,704

Title:Nasal administration
Abstract: A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Hafner; Roderick Peter (Swindon, GB)
Assignee: Optinose AS (Oslo, NO)
Application Number:14/274,271
Patent Claims: 1. A nasal delivery device for delivering g powdered sumatriptan substance to a nasal cavity of a human subject, the delivery device comprising: a nosepiece for fitting to the nasal cavity of the subject, and a capsule-containing member which contains a capsule, the capsule containing the powdered sumatriptan substance to be delivered to the nasal cavity of the subject, wherein the capsule-containing member includes a flow passage in which the capsule is disposed to be rotatable therewithin when an air flow is delivered therethrough, the flow passage including an inlet and an outlet which is in fluid communication with the nosepiece, wherein the device is configured such that, when the nosepiece is fitted to the nasal cavity of the subject, oral exhalation by the subject through the nosepiece acts to close the velum of the subject and drive an air flow through the nasal cavity, with the air flow passing into one nasal passage and out the other nasal passage, thereby achieving a bi-directional air flow, and wherein the powdered sumatriptan substance has a particle size distribution of 10% less than about 20 .mu.m, 50% less than about 50 .mu.m and 90% less than about 150 .mu.m.

2. The delivery device of claim 1, wherein the inlet of the flow passage includes an inlet aperture which provides a flow restriction to an air flow as delivered therethrough.

3. The delivery device of claim 2, wherein the inlet aperture provides a seat for a lower end of the capsule prior to delivery of an air flow through the flow passage.

4. The delivery device of claim 1, wherein the flow passage is an elongate flow passage and the capsule is oriented axially therealong.

5. The delivery device of claim 1, wherein the delivery device is a replaceable nosepiece unit.

6. The delivery device of claim 1, wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate.

7. The delivery device of claim 1, wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants.

8. The delivery device of claim 7, wherein the capsule contains 10 mg of sumatriptan succinate powder.

9. The delivery device of claim 1, wherein the powdered sumatriptan substance has a particle size distribution of 10% less than about 10 .mu.m, 50% less than about 30 .mu.m and 90% less than about 90 .mu.m.

10. A method of treating headache in a human subject, comprising: fitting a housing and a mouthpiece unit to a first delivery device of claim 1; piercing the capsule in the first delivery device; fitting the nosepiece of the first delivery device into a first nostril of the subject; and the subject exhaling through the mouthpiece unit to cause closure of the oropharyngeal velum of the subject and cause the capsule of the first delivery device to be rotated and release the powdered sumatriptan substance from within the capsule of the first delivery device and be entrained in an exhaled air flow.

11. The method of claim 10, further comprising: removing the housing and the mouthpiece unit from the first delivery device; fitting the housing and the mouthpiece unit to a second delivery device of claim 1; piercing the capsule in the second delivery device; fitting the nosepiece of the second delivery device into a second nostril of the subject; and the subject exhaling through the mouthpiece unit to cause closure of the oropharyngeal velum of the subject and cause the capsule of the second delivery device to be rotated and release the powdered sumatriptan substance from within the capsule of the second delivery device and be entrained in an exhaled air flow.

12. The method of claim 11, in the treatment of cluster headaches.

13. The method of claim 11, in the treatment of migraine.

14. The method of claim 11, wherein piercing a capsule in the first or second delivery device comprises piercing the capsule at first and second spaced locations along an axial length thereof, and the first and second spaced locations are above a height of the powdered sumatriptan substance as contained by the capsule.

15. A delivery device for delivering a powdered sumatriptan substance to a nasal cavity of a human subject, the delivery device comprising: a nosepiece for fitting to the nasal cavity of the subject, and a capsule-containing member which contains a capsule, the capsule containing the powdered sumatriptan substance to be delivered to the nasal cavity of the subject, the powdered sumatriptan substance containing only sumatriptan succinate and no introduced excipients or adjuvants, wherein the capsule-containing member includes a flow passage in which the capsule is disposed to be rotatable therewithin when an air flow is delivered therethrough, the flow passage including an inlet and an outlet which is in fluid communication with the nosepiece, wherein the device is configured such that, when the nosepiece is fitted to the nasal cavity of the subject, oral exhalation by the subject through the nosepiece acts to close the velum of the subject and drive an air flow through the nasal cavity, with the air flow passing into one nasal passage and out the other nasal passage, thereby achieving a bi-directional air flow, and wherein the powdered sumatriptan substance has a particle size distribution of 10% less than about 20 .mu.m, 50% less than about 50 .mu.m and 90% less than about 150 .mu.m.

16. The delivery device of claim 15, wherein the capsule contains 10 mg of sumatriptan succinate powder.

17. A nasal delivery device for delivering powdered sumatriptan to a nasal cavity of a human subject, the delivery device comprising: a nosepiece for fitting to the nasal cavity of the subject, and a capsule-containing member which contains a capsule, the capsule containing the powdered sumatriptan to be delivered to the nasal cavity of the subject, wherein the capsule-containing member includes a flow passage in which the capsule is disposed to be rotatable therewithin when an air flow is delivered therethrough, the flow passage including an inlet and an outlet which is in fluid communication with the nosepiece, and wherein the device is configured such that when, the nosepiece is fitted to the nasal cavity of the subject, oral exhalation by the subject through the nosepiece acts to close the velum of the subject and drive an air flow through the nasal cavity, with the air flow passing into one nasal passage and out the other nasal passage, thereby achieving a bi-directional air flow, and wherein the powdered sumatriptan has a particle size distribution of 10% less than about 20 .mu.m, 50% less than about 50 .mu.m and 90% less than about 150 .mu.m.

18. The delivery device of claim 17, wherein the powdered sumatriptan comprises a sumatriptan base or sumatriptan succinate.

19. The delivery device of claim 17, wherein the powdered sumatriptan contains only sumatriptan succinate and no introduced excipients or adjuvants.

20. The delivery device of claim 17, wherein the capsule contains 10 mg of sumatriptan succinate powder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc